Expression of Ki67 and clinicopathological features in breast cancer

Chinese Journal of Oncology

Volumn 36, Issue 4, 2014, Pages 273-275

  Wang, Baona ^a   Wang, Xiang ^a   Wang, Jing ^a   Xuan, Lixue ^a   Wang, Zhongzhao ^a   Wang, Xin ^a   Gao, Jidong ^a   Zhang, Haizeng ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Breast neoplasms; Gene expression; Ki67; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN;

AGE; ANTIGEN EXPRESSION; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER SIZE; CLINICAL FEATURE; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; LUMINAL A BREAST CANCER; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER; ADULT; AGED; BREAST TUMOR; CANCER STAGING; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84925287264     PISSN: 02533766     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3766.2014.04.007     Document Type: Article

References (11)

1. Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation[J]. Int J Cancer, 1983, 31(1):13-20.
2. Nishimura R, Osako T, Okumura Y, et al. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer [J]. Exp Ther Med, 2010, 1(5):747-754.
3. Molino A, Micciolo R, Turazza M, et al. Ki-67 immunostaining in 322 primary breast cancers; associations with clinical and pathological variables and prognosis[J]. Int J Cancer, 1997, 74(4):433437.
4. Locker AP, Birrell K, Bell JA, et al. Ki67 immunoreactivity in breast carcinoma; relationships to prognostic variables and short term survival [J]. Eur J Surg Oncol, 1992, 18(3):224-229.
5. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature, 2000, 406(6797):747-752.
6. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets [J]. Proc Natl Acad Sci U S A, 2003, 100(14):8418-8423.
7. Railo M, Nordling S, Von Boguslawsky K, et al. Prognostic value of Ki-67 immunolabelling in primary operable breast cancer[J]. Br J Cancer, 1993, 68(3):579-583.
8. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer[J]. J Natl Cancer Inst, 2009, 101(10):736-750.
9. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes: dealing with the diversity of breast cancer; highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J]. Ann Oncol, 2011, 22(8):1736-1747.
10. Viale G, Giobbie-Hurder A, Regan MM, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer; results from Breast International Croup Trial 1-98 comparing adjuvant tamoxifen with letrozole [J]. J Clin Oncol, 2008, 26(34):5569-5575.
11. Viale G, Regan MM, Mastropasqua MG, et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer [J]. J Natl Cancer Inst, 2008, 100(3):207-212.